US00847X1046

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivatat ASH 2024 and Provides Regulatory Update on Mitapivat

– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – –…

4 days ago